Meridiem Capital Partners’s Twist Bioscience TWST Stock Holding History

Meridiem Capital Partners’s Portfolio TWST Stock Details TWST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-239,669	Closed	-$11.4M	–	117
2026 Q1	$11.4M	Buy	239,669 +218,464	+1,030%	+$9.79M	0.74%	46
2025 Q4	$673K	Buy	+21,205	New	+$662K	0.04%	71
2025 Q2	–	Sell	-78,845	Closed	-$3.1M	–	95
2025 Q1	$3.1M	Buy	+78,845	New	+$3.55M	0.32%	54

Other funds holding TWST

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Meridiem Capital Partners's TWST Position: Q2 2026 in Review

Meridiem Capital Partners sold out of Twist Bioscience (TWST) in Q2 2026, closing a stake of 239,669 shares — an estimated $11.4M sold.

Meridiem Capital Partners first reported a position in TWST in Q1 2025 and held it in 3 quarters. The position peaked at $11.4M in Q1 2026. 336 funds tracked by Wall St. Rank hold TWST as of Q2 2026.

Meridiem Capital Partners reported no remaining Twist Bioscience position as of Q2 2026 after selling out during the quarter.
Meridiem Capital Partners sold 239,669 Twist Bioscience shares in Q2 2026, an estimated $11.4M.
Meridiem Capital Partners first reported a position in Twist Bioscience in Q1 2025 and held it in 3 quarters.
Meridiem Capital Partners's Twist Bioscience position peaked at $11.4M in Q1 2026.
336 funds tracked by Wall St. Rank held Twist Bioscience as of Q2 2026.

Based on Meridiem Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.